Transgender hormone therapy (female-to-male) to individuals taking bioidentical hormones in the form of testosterone (including esters) and do not apply to those taking synthetic AAS (e.g., nandrolone) or dihydrotestosterone. Transgender hormone therapy (female-to-male) Transgender hormone therapy of the female-to-male (FTM) type, also known as masculinizing hormone therapy, is a form of hormone therapy and sex reassignment therapy which is used to change the secondary sexual characteristics of transgender people from feminine (or androgynous) to masculine. It is one of two types of transgender hormone therapy (the other being male-to-female), and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people
Fraternal birth order and male sexual orientation sexual orientation via the fraternal birth order effect (for example, homosexual men with no older brothers) owe their homosexuality to other causes such as certain polymorphic genes (colloquially called "gay genes") or prenatal hormone levels during fetal development. Both direct and indirect evidence have demonstrated that the mechanism by which the fraternal birth order effect operates is prenatal in timing and biological in nature, rather than postnatal in timing or psychosocial in nature. Indirect evidence was found first when it was discovered that the fraternal birth order effect interacts with birth weight. Then, Bogaert (2006) produced direct evidence that the